Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Pancreatic Neoplasms 2Pancreatic Diseases 2Carcinoma, Pancreatic Ductal 2Prostatic Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × MK-4721 × Clear all
NCT01608711 2017-05-16

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Astellas Pharma Inc

Phase 2 Completed
2 enrolled
Gastrointestinal

Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT00902291 2015-09-14

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Astellas Pharma Inc

Phase 2 Completed
205 enrolled
Gastrointestinal

Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT00519233 2014-05-02

AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

Astellas Pharma Inc

Phase 1 Completed
13 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡